C9orf72 and Cognitive impairment: An open-label study (NCT05189106) is evaluating the potential effects of baricitinib therapy on patients with subjective cognitive disorder, mild cognitive impairment, Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers of an ALS-related gene (as hexanucleotide expansion in the C9orf72), with evidence of abnormal inflammatory signaling in cerebrospinal fluid (CSF) at baseline.